Peptide Chemical Synthesis
We manufacture peptide APIs by chemical synthesis using AJIPHASE™ — our proprietary liquid-phase synthesis platform. From short and medium-length sequences to longer peptides assembled by fragment condensation, and from standard linear sequences to cyclic, disulfide-constrained, PEGylated, or lipidated variants, our team designs and optimizes the right synthesis route from first material through GMP supply.
Chemical Synthesis Services
Peptide Synthesis
Peptide synthesis for linear, modified, and complex sequences, including GLP-1 analogs, with flexible scale-up options from grams to kilograms.
Process Development
Synthesis route design and optimization for short, long, and modified peptides — coupling efficiency, deprotection conditions, fragment strategy, and purification — to build a robust, scalable process before clinical manufacturing.
Analytical Characterization
Phase-appropriate in-house analytical development for peptide quality attributes, including purity, identity, related impurities, residual solvents, endotoxin, and impurity profiling.
GMP Manufacturing
GMP peptide manufacturing from clinical to commercial scale, supported by scalable AJIPHASE™ liquid-phase synthesis, robust manufacturing processes, and experience with complex and modified peptides.
CMC Support
CMC support across development stages, including process descriptions, analytical method summaries, characterization data, and documentation to support global regulatory submissions and lifecycle activities.
Technology Transfer
For programs moving to in-house manufacturing or partner CDMO, full technology transfer support is provided, including process descriptions, batch records, analytical method transfer, and on-site training.
Why Choose AJIPHASE™ for Peptide Chemical Synthesis
AJIPHASE™ enables scalable liquid-phase peptide synthesis using standard manufacturing equipment, with reduced solvent and reagent consumption. Its flexible chemistry supports a broad range of peptide sequences and modifications from development through commercial manufacturing.
Scale When You Need It
AJIPHASE™ offers flexible manufacturing scales and straightforward scale-up, with production volumes adjusted to reactor size and program needs.
Lower Solvent and Reagent Consumption vs. SPPS
Even at small scale, AJIPHASE™ requires fewer equivalents of activating reagents and less solvent per cycle than solid-phase synthesis. Quantifiable improvement in PMI — confirmed via our EcoPass sustainability tool.
Broad Modification Support in a Single Platform
Cyclic peptides, disulfide-bridged structures, PEGylated variants, lipidated sequences, non-natural amino acids — the modifications that define modern peptide therapeutics are all supported within the same AJIPHASE™ workflow.
Standard Equipment — Straightforward Technology Transfer
AJIPHASE™ runs in standard chemical reactors — no proprietary synthesizer hardware required. For programs moving to in-house manufacturing or partner CDMOs, technology transfer can be implemented efficiently.
Longer Sequences by Fragment Condensation
Fragment-based synthesis gives long-chain peptide programs a route forward — and a single partner from development through commercial supply.
Fragment-Based Synthesis
Long peptides assembled via fragment condensation, with peptide fragments synthesized separately and then coupled to enable sequences beyond the practical limits of continuous-chain elongation.
Commercial-Scale Manufacturing
AJIPHASE™ enables customer programs to progress from development to commercial manufacturing within the same liquid-phase platform. No platform switch is required as programs scale, supporting continuity in process and CMC strategy.
Natural-Sequence Peptides at Large Volumes
For long peptides composed of natural amino acids and required at very large commercial volumes, CORYNEX™ recombinant expression offers an alternative manufacturing route.
25+
Years of Peptide Synthesis Experience
>90%
Organic Solvent Reduction vs. SPPS
3
GMP Sites in Belgium & Japan
Manufacturing Facilities
Three GMP-capable sites in Belgium and Japan providing geographic reach and manufacturing flexibility for global programs.
Balen, Belgium
GMP peptide manufacturing capabilities, conventional liquid-phase synthesis, and flow chemistry technologies. Supports commercial production, scale-up, and long-term supply of peptide therapeutics.
Wetteren, Belgium
GMP manufacturing, conventional liquid-phase synthesis, and flow chemistry technologies. FDA and EMA inspected. Supports peptide programs requiring EU supply chain or EMA-compliant documentation.
Tokai, Japan
Primary AJIPHASE™ synthesis site. FDA and PMDA inspected. Capabilities from research scale through commercial GMP manufacturing, supported by integrated process and analytical development, manufacturing, and quality teams.
Tell Us About Your Peptide Synthesis Program
Our synthesis team assesses sequence, modifications, and scale requirements to determine fit and recommend the right approach, typically within a few business days.
Frequently Asked Questions
What sequence lengths can AJIPHASE™ synthesize?
AJIPHASE™ supports short and medium-length peptides, typically from 2 to approximately 50 amino acids. For sequences beyond this range, Ajinomoto Bio-Pharma Services uses fragment-based synthesis strategies via AJIPHASE™ or alternative routes — our team assesses the optimal approach based on your specific sequence, modifications, and scale requirements.
What peptide modifications does Ajinomoto Bio-Pharma Services support in chemical synthesis?
Ajinomoto Bio-Pharma Services supports a broad range of modifications for short and medium peptides via AJIPHASE™, including: cyclic peptides (head-to-tail and side-chain cyclization), disulfide-bridged structures, PEGylated and lipidated peptides, D-amino acid incorporation, non-natural amino acids, phosphopeptides, and fluorescent or biotin-labeled sequences. Confirm specific modifications with the Aji Bio-Pharma peptide team — the list above reflects standard capability, not the full scope of what we can support. Cyclic, disulfide-bridged (including multi-disulfide), and PEGylated peptides are handled within the same liquid-phase synthesis workflow; for lipidated peptides and other conjugates, Aji Bio-Pharma evaluates the optimal conjugation strategy for each sequence.
What is the turnaround time for research-grade peptide synthesis at Ajinomoto Bio-Pharma Services?
Typical research-grade turnaround depends on sequence length and modifications; the Ajinomoto Bio-Pharma Services team provides a timeline estimate at program assessment.
What GMP regulatory frameworks does Ajinomoto Bio-Pharma Services support for synthetic peptide APIs?
Ajinomoto Bio-Pharma Services supports GMP manufacturing of synthetic peptide APIs across multiple global sites, with facilities inspected by major regulatory authorities including FDA, EMA, and PMDA. The Aji Bio-Pharma manufacturing network supports clinical through commercial programs using conventional liquid-phase synthesis, AJIPHASE™, and flow chemistry. The optimal site is selected based on program scale, technical requirements, regulatory needs, and supply chain considerations.
How do I get started with a peptide synthesis program at Ajinomoto Bio-Pharma Services?
To get started, share your sequence, key modifications, target scale, and regulatory stage with the Ajinomoto Bio-Pharma Services team. Aji Bio-Pharma experts will assess fit, recommend the right synthesis route, and outline a development pathway. Most programs begin with a brief technical discussion before moving into a formal proposal process.